For some of the measurements (i.e., total IGF‐I, IGFBP‐3, and PAPP‐A), we observed statistically significant but hardly biologically relevant differences between median values for women with cancer compared with well‐matched controls, whereas the remaining measurements (i.e., IGFBP‐2, bioactive IGF, total IGF‐II, and pro‐IGF‐II) did not differ between the two groups. This evidence concerns the gene IGF2 and cancer.